The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Astra Rises On Positive Trial Results

Fri, 29th May 2020 10:59

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.

----------

FTSE 100 - WINNERS

----------

AstraZeneca, up 1.9%. The drugmaker said its phase 3 Adaura trial of Tagrisso in early-stage cell lung cancer found that the drug reduced the risk of disease recurrence or death by around 80%. The detailed results were from a trial of Tagrisso, the brand name for osimertinib, after surgery in patients with "epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer after complete tumour resection with curative intent". EGFR mutations are associated with some lung cancers. In the primary endpoint of disease-free survival in patients with stage 2 and 3A disease, treatment with Tagrisso reduced risk of disease recurrence or death by 83%. Disease-free survival in the overall trial population, covering stages 1B to 3A, found a 79% drop in the risk of disease recurrence or death. At the two year mark, 89% of patients in the trial who had been treated with Tagrisso were still alive and disease free compared to a 53% figure in patients who were given a placebo.

----------

FTSE 100 - LOSERS

----------

Fresnillo, down 2.3%. The Mexican gold miner said it is responding to operational challenges caused by Covid-19 after a tough 2019. Fresnillo said it has focused on responding to the Covid-19 over the past three months, implementing a range of safety measures across the business. It confirmed that the board and senior management took voluntary and temporary pay cuts to help the company get through this "unprecedented" situation. Fresnillo said its operations are critical to the economies in which it operate, with mining now confirmed as an essential activity in Mexico. "Operationally, 2019 was a more challenging year, as expected," said Chair Alberto Bailleres. Both silver and gold production fell from 2018 levels, due to lower-than-anticipated grades in its key mines. The company said its response has been to increase the pace and scale of investments in a series of projects and take corrective actions to bring production back to acceptable levels in the short-term, and to achieve steady growth in future years.

----------

FTSE 250 - WINNERS

----------

Provident Financial, up 8.4%. The lender got an upgrade from Jefferies to Buy from Hold.

----------

B&M European Value Retail, up 4.1%. The retailer reported a strong end to the fourth quarter - which ran to March 28 - driven by an exceptionally strong March performance in Grocery, with the B&M UK fascia like-for-like revenue up 6.6%. Going forward, B&M said it experienced strong revenue growth in the first 8 weeks to May 23, with B&M UK fascia like-for-like revenue up 23%, driven by exceptionally strong Do It Yourself and Gardening categories, and despite a significant fall in customer count. If DIY and Gardening categories are excluded, the B&M UK fascia like-for-like revenue over that 8 week period was up 10%. "We have encountered exceptionally strong demand in our UK business over recent weeks. Customers have been coming to our stores much less frequently through the lockdown but their average spend has been much higher than normal," said Chief Executive Simon Arora.

----------

FTSE 250 - LOSERS

----------

Energean, down 2.0%. The oil & gas producer said its shareholder gave a green light for the name change from Energean Oil & Gas PLC to Energean PLC. In terms of trading, the company noted that it retains its strong commitment to sustainable development regardless of the impact of the global Covid-19 pandemic.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Helios Underwriting, up 9.1%. The insurance company reported profit before impairments and tax of GBP2.4 million for 2019 compared to GBP608,000 a year prior. Adjusted net asset value per share grew to GBP2.06 from GBP1.90 year-on-year. Helios said, during 2019, a further four corporate members were acquired, resulting in a 31% increase in the capacity portfolio. The four acquisitions in 2019 were purchased for a total consideration of GBP10 million, the company said. Helios said it will not be paying a dividend for 2019, having paid 3.0 pence a share in 2018. The company explained that it intends to maintain its available cash resources, given the uncertainty for the potential funding of the Covid-19 and other losses in the immediate future. "The coronavirus pandemic will be a manageable loss for the property and casualty insurance and reinsurance industry, unless there is some kind of structural change to drive the cost to the sector much higher," said Non-Executive Chair Michael Cunningham.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Johnson Service Group , down 9.3% at 129.64p. The textile services provider said it intends to raise GBP85 million through the issue of 73.9 million shares at a price of 115p. The company said the placing will be conducted through an accelerated bookbuilding process, which will be launched immediately. Investec Bank is acting as sole broker and sole bookrunner in connection with the placing. Johnson Service said it is fundraising to improve its liquidity position and further strengthen its balance sheet. The company explained that trading for the first two months of 2020, before the impact of Covid-19, was in line with its expectations, but it continues to see a significant amount of disruption across its markets. However, Johnson Service said the full implications of Covid-19 on its financial performance and position are difficult to determine at this stage.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more
19 Feb 2024 15:59

London close: Stocks manage gains on globally quiet day

(Sharecast News) - London's financial markets finished in positive territory on Monday, with stocks closing in the green after overcoming minor losses earlier in the session.

Read more
19 Feb 2024 15:39

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

(Alliance News) - AstraZeneca PLC on Monday said it has completed the acquisition of Icosavax Inc.

Read more
19 Feb 2024 11:51

LONDON MARKET MIDDAY: Stocks lack direction amid quiet start to week

(Alliance News) - Stock prices in London lacked direction at midday Monday, amid a quiet start to the week.

Read more
19 Feb 2024 08:44

LONDON MARKET OPEN: Stocks drift; Currys surges on takeover interest

(Alliance News) - Stock prices in London were looking for direction early Monday, as investors weighed possible trajectories for US interest rate cuts and a China's economic recovery.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.